Regenxbio (NASDAQ:RGNX) is an analyst favorite. In the past year, upgrades to “Buy” and “Outperform” have spurred on investors. In the biotechnology sector, the potential for price movement is big and currently, all eyes are on RGNX stock.
So should you be keeping yours here too?
RGNX Stock – All Eyes Are On ItThe company’s portfolio is on the verge of potentially significant revenue as gene therapies that use its technology are close to FDA approval. This, of course, would mean big business for Regenxbio.
It’s “adeno-associated viral (AAV) vectors” are ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.